ACMR Stock Analysis: Acm Research | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 5.606m USD | 12M Return: 154.1% | US00108J1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 64.5M
EPS Trend: -35.4%
Qual. Beats: 2
Rev. Trend: 97.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 8.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ACM Research is a U.S.-headquartered (Fremont, California) maker of semiconductor capital equipment, founded in 1998 and listed on NASDAQ. The company designs, manufactures, and sells two main product lines: front-end process tools, led by single-wafer wet cleaning systems built on its proprietary SAPS, TEBO, and Tahoe technologies, along with electrochemical plating (ECP), furnace, PECVD, and track platforms; and advanced packaging equipment, including coaters, developers, photoresist strippers, scrubbers, wet etchers, and copper-plating tools sold under the Ultra C and Ultra ECP families. Sales are made primarily across Mainland China and other international markets through a direct sales force and third-party representatives.
The company sits in the Semiconductor Materials & Equipment sub-industry, serving foundries, memory producers, and OSAT (outsourced semiconductor assembly and test) customers. Wet cleaning is a repeat-use step that runs at multiple points in wafer fabrication, which tends to make cleaning tool demand somewhat less cyclical than other equipment categories, while ACMRs packaging exposure links it to growth in advanced packaging formats such as 2.5D and 3D integration used for high-performance computing and AI chips.
- China semiconductor capex drives cleaning tool orders
- US export controls threaten China revenue exposure
- Advanced packaging tools gain from AI chip demand
| Net Income: 150.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -2.67 > 1.0 |
| NWC/Revenue: 201.2% < 20% (prev 119.6%; Δ 81.69% < -1%) |
| CFO/TA -0.00 > 3% & CFO -6.60m > Net Income 150.2m |
| Net Debt (-1.10b) to EBITDA (270.4m): -4.08 < 3 |
| Current Ratio: 3.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.8m) vs 12m ago 6.48% < -2% |
| Gross Margin: 43.84% > 18% (prev 49.40%; Δ -5.56% > 0.5%) |
| Asset Turnover: 38.16% > 50% (prev 39.96%; Δ -1.80% > 0%) |
| Interest Coverage Ratio: 31.87 > 6 (EBIT TTM 243.2m / Interest Expense TTM 7.63m) |
| A: 0.61 (Total Current Assets 2.87b - Total Current Liabilities 786.3m) / Total Assets 3.40b |
| B: 0.13 (Retained Earnings 456.7m / Total Assets 3.40b) |
| C: 0.09 (EBIT TTM 243.2m / Avg Total Assets 2.72b) |
| D: 1.87 (Book Value of Equity 1.86b / Total Liabilities 994.1m) |
| Altman-Z'' = 7.03 = AAA |
| DSRI: 1.00 (Receivables 605.2m/477.4m, Revenue 1.04b/815.2m) |
| GMI: 1.13 (GM 49.40% / 43.84%) |
| AQI: 0.98 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.27 (Revenue 1.04b / 815.2m) |
| TATA: 0.05 (NI 150.2m - CFO -6.60m) / TA 3.40b) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of August 29, 2026, the stock is trading at USD 74.42 with a total of 888,127 shares traded. Over the past week, the price has changed by -6.28%, over one month by +3.33%, over three months by -19.86% and over the past year by +154.08%.
Current recommended Stop Loss: 59.60 (which is 19.9% or 2.4 ATR below the current price).
Acm Research has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ACMR.
- StrongBuy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 117.8 | 58.2% |
P/E Trailing = 37.967
P/E Forward = 38.3142
P/S = 5.402
P/B = 2.9621
Revenue TTM = 1.04b USD
EBIT TTM = 243.2m USD
EBITDA TTM = 270.4m USD
Long Term Debt = 192.9m USD (from longTermDebt, last quarter)
Short Term Debt = 152.9m USD (from shortTermDebt, last quarter)
Debt = 357.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.41m
Net Debt = -1.10b USD (calculated: Debt 357.7m - CCE 1.46b)
Enterprise Value = 4.50b USD (5.61b + Debt 357.7m - CCE 1.46b)
Interest Coverage Ratio = 31.87 (Ebit TTM 243.2m / Interest Expense TTM 7.63m)
EV/FCF = -37.49x (Enterprise Value 4.50b / FCF TTM -120.1m)
FCF Yield = -2.67% (FCF TTM -120.1m / Enterprise Value 4.50b)
FCF Margin = -11.58% (FCF TTM -120.1m / Revenue TTM 1.04b)
Net Margin = 14.48% (Net Income TTM 150.2m / Revenue TTM 1.04b)
Gross Margin = 43.84% ((Revenue TTM 1.04b - Cost of Revenue TTM 582.9m) / Revenue TTM)
Gross Margin QoQ = 45.96% (prev 46.37%)
Tobins Q-Ratio = 1.32 (Enterprise Value 4.50b / Total Assets 3.40b)
Interest Expense / Debt = 2.13% (Interest Expense 7.63m / Debt 357.7m)
Taxrate = 11.25% (26.5m / 235.6m)
NOPAT = 215.9m (EBIT 243.2m * (1 - 11.25%))
Current Ratio = 3.66 (Total Current Assets 2.87b / Total Current Liabilities 786.3m)
Debt / Equity = 0.19 (Debt 357.7m / totalStockholderEquity, last quarter 1.86b)
Debt / EBITDA = -4.08 (Net Debt -1.10b / EBITDA 270.4m)
Debt / FCF = 9.18 (negative FCF - burning cash) (Net Debt -1.10b / FCF TTM -120.1m)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.52% (Net Income 150.2m / Total Assets 3.40b)
RoE = 9.48% (Net Income TTM 150.2m / Total Stockholder Equity 1.58b)
RoCE = 13.68% (EBIT 243.2m / Capital Employed (Equity 1.58b + L.T.Debt 192.9m))
RoIC = 7.95% (NOPAT 215.9m / Invested Capital 2.71b)
WACC = 15.97% (E(5.61b)/V(5.96b) * Re(16.87%) + D(357.7m)/V(5.96b) * Rd(2.13%) * (1-Tc(0.11)))
Discount Rate = 16.87% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 89.67 | Cagr: 3.67%
[DCF] Fair Price = unknown (Cash Flow -120.1m)
EPS Correlation: -35.35 | EPS CAGR: -8.52% | SUE: 2.38 | # QB: 2
Revenue Correlation: 97.60 | Revenue CAGR: 26.86% | SUE: 1.72 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.48 | Chg30d=+1.42% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=2.15 | Chg30d=+28.45% | Revisions=+25% | GrowthEPS=+33.8% | GrowthRev=+30.0%
EPS next Year (2027-12-31): EPS=2.89 | Chg30d=+28.38% | Revisions=+25% | GrowthEPS=+34.3% | GrowthRev=+29.3%
[Analyst] Revisions Ratio: +50% (up=3, down=0)